Azenta (NASDAQ:AZTA) Issues Earnings Results

Azenta (NASDAQ:AZTA) released its quarterly earnings results on Tuesday. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.11 by $0.17, FiscalAI reports. Azenta had a negative net margin of 20.63% and a positive return on equity of 1.18%. The business had revenue of $167.09 million during the quarter, compared to analyst estimates of $160.21 million.

Azenta Price Performance

NASDAQ AZTA traded down $0.47 during trading on Tuesday, hitting $40.48. The company’s stock had a trading volume of 675,892 shares, compared to its average volume of 938,985. Azenta has a fifty-two week low of $15.93 and a fifty-two week high of $46.41. The company has a market cap of $1.77 billion, a PE ratio of -14.67 and a beta of 1.47. The business’s 50 day simple moving average is $35.48 and its 200-day simple moving average is $28.47.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Needham & Company LLC reissued a “buy” rating and set a $37.00 target price on shares of Azenta in a research report on Monday, September 14th. Weiss Ratings upgraded shares of Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 26th. Finally, Wall Street Zen lowered shares of Azenta from a “buy” rating to a “hold” rating in a report on Sunday, October 18th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $41.20.

Azenta Company Profile

Azenta, Inc. provides products and services for life sciences research and the management of biological samples. Its offerings include automated sample storage systems, laboratory automation equipment, consumables, and software used to track and manage samples. The company also provides genomic services through GENEWIZ, including sequencing and other genetic analysis services for researchers and organizations in the life sciences and pharmaceutical industries. Azenta was formed in 2021 when Brooks Automation separated its life sciences business and adopted the Azenta name.